Latest Telik Inc (TELK) Headlines
Nasdaq stocks posting largest volume increases
AP - Wed Mar 12, 5:02PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
Telik Announces Fourth Quarter And 2013 Year End Financial Results
PR Newswire - Mon Mar 10, 3:15PM CDT
Telik, Inc. (Nasdaq: TELK) reported a net loss of $0.8 million, or $0.17 per share, for the three months ended December 31, 2013, compared with a net loss of $1.8 million, or $0.66 per share, for the comparable period in 2012. For the year ended December 31, 2013, net loss was $5.2 million, or $1.17 per share, compared with a net loss of $8.0 million, or $3.64 per share, for the year ended December 31, 2012.
Sears Holdings Announces Date For 2014 Annual Meeting Of Stockholders
PR Newswire - Wed Jan 22, 3:47PM CST
Sears Holdings Corporation (NASDAQ: SHLD) announced today that the 2014 annual meeting of stockholders will be held at the Company's headquarters in Hoffman Estates, Ill., on Tuesday, May 6, 2014.
'Why De-Registered Parties Joined PDP'
by Misbahu Bashir - All Africa Global Media - Tue Jan 21, 3:32AM CST
Chairman of the defunct United Nigeria Peoples Party (UNPP) Alhaji Inuwa Ahmed, yesterday at a media briefing in Kaduna explained why 23 de-registered political parties joined the ruling People's Democratic Party (PDP).
Tekmira Doses First Subject in Human Clinical Trial of TKM-Ebola
GlobeNewswire - Tue Jan 14, 12:52PM CST
Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today announced that it has dosed the first subject in a Phase I human clinical trial of TKM-Ebola, an anti-Ebola viral therapeutic that is being developed under a US$140 million contract with the U.S. Department of Defense.
Tesla Provides Customers With Upgraded Charging Software and Adapter
Marketwire - Fri Jan 10, 3:51PM CST
A variety of factors such as corrosion, physical damage to receptacles, or inappropriate wiring or installation of electrical outlets can cause higher than normal electrical resistance when using the Universal Mobile Connector ("UMC") NEMA 14-50 adapters to charge Tesla Model S vehicles. When charging, higher than normal electrical resistance connections to external energy sources may cause excessive heating of the adapter. In December 2013, Tesla released an over-the-air software update to address this issue, enabling the Model S onboard charging system to automatically reduce the charging current by 25 percent if it detects unexpected fluctuations in the input power to the vehicle. This fully addresses the issue by substantially reducing the heat generated in any high resistance connections outside the vehicle. This update increases robustness and safety considerably in the unlikely event that a home wiring system, receptacle, adapter or cord is unable to meet its rated current capacity.
Telik Announces Third Quarter 2013 Financial Results
PR Newswire - Tue Nov 12, 3:20PM CST
Telik, Inc. (Nasdaq: TELK) today reported a net loss of $1.1 million, or $0.25 per share, for the third quarter ended September 30, 2013, compared with a net loss of $1.9 million, or $0.78 per share for the comparable period in 2012.
OTC Signal Daily Stock Watch - Telik, Inc., (NASDAQ: TELK)
WorldStockWire - Wed Sep 04, 1:45AM CDT
OTC Signal tracks stocks daily and is pleased to offer its stock alerts. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Signal at the following: http://www.otcsignal.com
Colon Cancer - Pipeline Review, H2 2013 Gives Coverage of the Colon Cancer Pipeline on the Basis of Route of Administration and Molecule Type
M2 - Mon Aug 12, 12:10PM CDT
Research and Markets (http://www.researchandmarkets.com/research/kfjngz/colon_cancer) has announced the addition of the "Colon Cancer - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Colon Cancer - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Colon Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Colon Cancer. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Colon Cancer. - A review of the Colon Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - AEterna Zentaris Inc. - Advenchen Laboratories, LLC - Affichem - Alethia Biotherapeutics Inc. - AlphaVax, Inc. - Cell Therapeutics, Inc. - Curis, Inc. - Cytokinetics, Inc - DEKK-TEC, Inc. - Eli Lilly and Company - Etubics Corporation - Five Prime Therapeutics, Inc. - Geistlich Pharma AG - ISA Pharmaceuticals B.V. - Isofol Medical AB - Kalos Therapeutics, Inc. - Lorus Therapeutics Inc - MabVax Therapeutics, Inc. - Northwest Biotherapeutics, Inc. - NovaLead Pharma Pvt. Ltd. - OncoMed Pharmaceuticals, Inc. - OncoVista Innovative Therapies, Inc. - Patrys Limited - PharmaMar, S.A. - Pharminox Limited - Pique Therapeutics - Tautatis Incorporated - Telik, Inc. - Transgene Biotek Ltd - Viventia Biotechnolo For more information visit http://www.researchandmarkets.com/research/kf...lon_cancer About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Telik Announces Second Quarter 2013 Financial Results
PR Newswire - Fri Aug 09, 3:15PM CDT
Telik, Inc. (Nasdaq: TELK) today reported a net loss of $1.4 million, or $0.30 per share, for the second quarter ended June 30, 2013, compared with a net loss of $2.1 million, or $1.11 per share for the comparable period in 2012.
Acute Promyelocytic Leukemia - Pipeline Review, H1 2013
M2 - Tue Jul 16, 9:46AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hn2mbb/acute) has announced the addition of the "Acute Promyelocytic Leukemia - Pipeline Review, H1 2013" report to their offering. 'Acute Promyelocytic Leukemia - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Acute Promyelocytic Leukemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Acute Promyelocytic Leukemia. Scope - A snapshot of the global therapeutic scenario for Acute Promyelocytic Leukemia. - A review of the Acute Promyelocytic Leukemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature
Market Maker Surveillance Report. TELK, FSLR, IEP, KNDI, ECTE, AOSL, Losing Stocks With Lowest Price Friction For Wednesday, June 12th 2013
M2 - Thu Jun 13, 2:20AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Wednesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Wednesday there were 3761 companies with "abnormal" market making, 1577 companies with positive Friction Factors and 3797 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage loss per share Wednesday and low price friction (bearish). This means that there was more selling than buying in the stocks and their stock prices dropped faster with less Friction. Telik Inc (NASDAQ:TELK), First Solar Inc (NASDAQ:FSLR), Icahn Enterprises LP (NASDAQ:IEP), Kandi Technologies Corp (NASDAQ:KNDI), Echo Therapeutics Inc (NASDAQ:ECTE), Alpha and Omega Semiconductor Ltd (NASDAQ:AOSL). To access Friction Factor, Naked Short Data a
Telik Announces First Quarter 2013 Financial Results
PR Newswire - Fri May 10, 3:30PM CDT
Telik, Inc. (Nasdaq: TELK) today reported financial results for the first quarter ended March 31, 2013. The net loss for the quarter ended March 31, 2013 was $1.9 million, or $0.46 per share, compared with a net loss of $2.3 million, or $1.25 per share, for the same period in 2012.
Mantle Cell Lymphoma - Pipeline Review, H1 2013 Featuring 22 Major Companies
M2 - Thu Apr 18, 6:22AM CDT
Research and Markets has announced the addition of the "Mantle Cell Lymphoma - Pipeline Review, H1 2013" report to their offering. 'Mantle Cell Lymphoma - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Mantle Cell Lymphoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Mantle Cell Lymphoma. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Mantle Cell Lymphoma. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Mantle Cell Lymphoma pipeline depth and focus of Indication t
Brain Tumor - Pipeline Review, H1 2013
M2 - Thu Mar 21, 4:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3zmbpg/brain_tumor) has announced the addition of the "Brain Tumor - Pipeline Review, H1 2013" report to their offering. Global Markets Direct's, 'Brain Tumor - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Brain Tumor, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Brain Tumor. Scope - A snapshot of the global therapeutic scenario for Brain Tumor. - A review of the Brain Tumor products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therap
Telik reduces loss to USD8.0m in 2012
M2 - Mon Mar 18, 10:46AM CDT
Telik Inc (Nasdaq:TELK), a clinical stage drug development company, on Friday reported a net loss of USD8.0m, or USD3.64 per share, for the year 2012, ended 31 December 2012.
Telik Announces Fourth Quarter And 2012 Year End Financial Results And 2013 Financial Guidance
PR Newswire - Fri Mar 15, 3:30PM CDT
Telik, Inc. (Nasdaq: TELK) reported a net loss of $1.8 million, or $0.66 per share, for the three months ended December 31, 2012, compared with a net loss of $2.5 million, or $1.38 per share, for the comparable period in 2011. For the year ended December 31, 2012, net loss was $8.0 million, or $3.64 per share, compared with a net loss of $12.0 million, or $6.69 per share, for the year ended December 31, 2011. Net loss per share for both periods were adjusted for the 1-for-30 reverse split of the company's common stock effected on March 30, 2012.
TELK, ATUSF, Removed From Naked Short Lists Today
M2 - Tue Feb 05, 9:36AM CST
BUYINS.NET, www.buyins.net , announced today that these select companies have been Removed From the NASDAQ, AMEX, NYSE, OTCBB and Pinksheet naked short threshold lists. Telik Inc (NASDAQ:TELK), ALTIUS MINERALS CORPORATION (OTC:ATUSF). For a complete list of companies on the naked short lists please visit our web site. To find the SqueezeTrigger Price before a short squeeze starts in any stock, go to http://www.buyins.net .
Nasdaq stocks posting largest volume increases
AP - Wed Mar 12, 5:02PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
Telik Announces Fourth Quarter And 2013 Year End Financial Results
PR Newswire - Mon Mar 10, 3:15PM CDT
Telik, Inc. (Nasdaq: TELK) reported a net loss of $0.8 million, or $0.17 per share, for the three months ended December 31, 2013, compared with a net loss of $1.8 million, or $0.66 per share, for the comparable period in 2012. For the year ended December 31, 2013, net loss was $5.2 million, or $1.17 per share, compared with a net loss of $8.0 million, or $3.64 per share, for the year ended December 31, 2012.
Sears Holdings Announces Date For 2014 Annual Meeting Of Stockholders
PR Newswire - Wed Jan 22, 3:47PM CST
Sears Holdings Corporation (NASDAQ: SHLD) announced today that the 2014 annual meeting of stockholders will be held at the Company's headquarters in Hoffman Estates, Ill., on Tuesday, May 6, 2014.
'Why De-Registered Parties Joined PDP'
by Misbahu Bashir - All Africa Global Media - Tue Jan 21, 3:32AM CST
Chairman of the defunct United Nigeria Peoples Party (UNPP) Alhaji Inuwa Ahmed, yesterday at a media briefing in Kaduna explained why 23 de-registered political parties joined the ruling People's Democratic Party (PDP).
Tekmira Doses First Subject in Human Clinical Trial of TKM-Ebola
GlobeNewswire - Tue Jan 14, 12:52PM CST
Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today announced that it has dosed the first subject in a Phase I human clinical trial of TKM-Ebola, an anti-Ebola viral therapeutic that is being developed under a US$140 million contract with the U.S. Department of Defense.
Tesla Provides Customers With Upgraded Charging Software and Adapter
Marketwire - Fri Jan 10, 3:51PM CST
A variety of factors such as corrosion, physical damage to receptacles, or inappropriate wiring or installation of electrical outlets can cause higher than normal electrical resistance when using the Universal Mobile Connector ("UMC") NEMA 14-50 adapters to charge Tesla Model S vehicles. When charging, higher than normal electrical resistance connections to external energy sources may cause excessive heating of the adapter. In December 2013, Tesla released an over-the-air software update to address this issue, enabling the Model S onboard charging system to automatically reduce the charging current by 25 percent if it detects unexpected fluctuations in the input power to the vehicle. This fully addresses the issue by substantially reducing the heat generated in any high resistance connections outside the vehicle. This update increases robustness and safety considerably in the unlikely event that a home wiring system, receptacle, adapter or cord is unable to meet its rated current capacity.
Telik Announces Third Quarter 2013 Financial Results
PR Newswire - Tue Nov 12, 3:20PM CST
Telik, Inc. (Nasdaq: TELK) today reported a net loss of $1.1 million, or $0.25 per share, for the third quarter ended September 30, 2013, compared with a net loss of $1.9 million, or $0.78 per share for the comparable period in 2012.
OTC Signal Daily Stock Watch - Telik, Inc., (NASDAQ: TELK)
WorldStockWire - Wed Sep 04, 1:45AM CDT
OTC Signal tracks stocks daily and is pleased to offer its stock alerts. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Signal at the following: http://www.otcsignal.com
Colon Cancer - Pipeline Review, H2 2013 Gives Coverage of the Colon Cancer Pipeline on the Basis of Route of Administration and Molecule Type
M2 - Mon Aug 12, 12:10PM CDT
Research and Markets (http://www.researchandmarkets.com/research/kfjngz/colon_cancer) has announced the addition of the "Colon Cancer - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Colon Cancer - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Colon Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Colon Cancer. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Colon Cancer. - A review of the Colon Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - AEterna Zentaris Inc. - Advenchen Laboratories, LLC - Affichem - Alethia Biotherapeutics Inc. - AlphaVax, Inc. - Cell Therapeutics, Inc. - Curis, Inc. - Cytokinetics, Inc - DEKK-TEC, Inc. - Eli Lilly and Company - Etubics Corporation - Five Prime Therapeutics, Inc. - Geistlich Pharma AG - ISA Pharmaceuticals B.V. - Isofol Medical AB - Kalos Therapeutics, Inc. - Lorus Therapeutics Inc - MabVax Therapeutics, Inc. - Northwest Biotherapeutics, Inc. - NovaLead Pharma Pvt. Ltd. - OncoMed Pharmaceuticals, Inc. - OncoVista Innovative Therapies, Inc. - Patrys Limited - PharmaMar, S.A. - Pharminox Limited - Pique Therapeutics - Tautatis Incorporated - Telik, Inc. - Transgene Biotek Ltd - Viventia Biotechnolo For more information visit http://www.researchandmarkets.com/research/kf...lon_cancer About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Telik Announces Second Quarter 2013 Financial Results
PR Newswire - Fri Aug 09, 3:15PM CDT
Telik, Inc. (Nasdaq: TELK) today reported a net loss of $1.4 million, or $0.30 per share, for the second quarter ended June 30, 2013, compared with a net loss of $2.1 million, or $1.11 per share for the comparable period in 2012.
Acute Promyelocytic Leukemia - Pipeline Review, H1 2013
M2 - Tue Jul 16, 9:46AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hn2mbb/acute) has announced the addition of the "Acute Promyelocytic Leukemia - Pipeline Review, H1 2013" report to their offering. 'Acute Promyelocytic Leukemia - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Acute Promyelocytic Leukemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Acute Promyelocytic Leukemia. Scope - A snapshot of the global therapeutic scenario for Acute Promyelocytic Leukemia. - A review of the Acute Promyelocytic Leukemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature
Market Maker Surveillance Report. TELK, FSLR, IEP, KNDI, ECTE, AOSL, Losing Stocks With Lowest Price Friction For Wednesday, June 12th 2013
M2 - Thu Jun 13, 2:20AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Wednesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Wednesday there were 3761 companies with "abnormal" market making, 1577 companies with positive Friction Factors and 3797 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage loss per share Wednesday and low price friction (bearish). This means that there was more selling than buying in the stocks and their stock prices dropped faster with less Friction. Telik Inc (NASDAQ:TELK), First Solar Inc (NASDAQ:FSLR), Icahn Enterprises LP (NASDAQ:IEP), Kandi Technologies Corp (NASDAQ:KNDI), Echo Therapeutics Inc (NASDAQ:ECTE), Alpha and Omega Semiconductor Ltd (NASDAQ:AOSL). To access Friction Factor, Naked Short Data a
Telik Announces First Quarter 2013 Financial Results
PR Newswire - Fri May 10, 3:30PM CDT
Telik, Inc. (Nasdaq: TELK) today reported financial results for the first quarter ended March 31, 2013. The net loss for the quarter ended March 31, 2013 was $1.9 million, or $0.46 per share, compared with a net loss of $2.3 million, or $1.25 per share, for the same period in 2012.
Mantle Cell Lymphoma - Pipeline Review, H1 2013 Featuring 22 Major Companies
M2 - Thu Apr 18, 6:22AM CDT
Research and Markets has announced the addition of the "Mantle Cell Lymphoma - Pipeline Review, H1 2013" report to their offering. 'Mantle Cell Lymphoma - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Mantle Cell Lymphoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Mantle Cell Lymphoma. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Mantle Cell Lymphoma. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Mantle Cell Lymphoma pipeline depth and focus of Indication t
Brain Tumor - Pipeline Review, H1 2013
M2 - Thu Mar 21, 4:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3zmbpg/brain_tumor) has announced the addition of the "Brain Tumor - Pipeline Review, H1 2013" report to their offering. Global Markets Direct's, 'Brain Tumor - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Brain Tumor, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Brain Tumor. Scope - A snapshot of the global therapeutic scenario for Brain Tumor. - A review of the Brain Tumor products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therap
Telik reduces loss to USD8.0m in 2012
M2 - Mon Mar 18, 10:46AM CDT
Telik Inc (Nasdaq:TELK), a clinical stage drug development company, on Friday reported a net loss of USD8.0m, or USD3.64 per share, for the year 2012, ended 31 December 2012.
Telik Announces Fourth Quarter And 2012 Year End Financial Results And 2013 Financial Guidance
PR Newswire - Fri Mar 15, 3:30PM CDT
Telik, Inc. (Nasdaq: TELK) reported a net loss of $1.8 million, or $0.66 per share, for the three months ended December 31, 2012, compared with a net loss of $2.5 million, or $1.38 per share, for the comparable period in 2011. For the year ended December 31, 2012, net loss was $8.0 million, or $3.64 per share, compared with a net loss of $12.0 million, or $6.69 per share, for the year ended December 31, 2011. Net loss per share for both periods were adjusted for the 1-for-30 reverse split of the company's common stock effected on March 30, 2012.
TELK, ATUSF, Removed From Naked Short Lists Today
M2 - Tue Feb 05, 9:36AM CST
BUYINS.NET, www.buyins.net , announced today that these select companies have been Removed From the NASDAQ, AMEX, NYSE, OTCBB and Pinksheet naked short threshold lists. Telik Inc (NASDAQ:TELK), ALTIUS MINERALS CORPORATION (OTC:ATUSF). For a complete list of companies on the naked short lists please visit our web site. To find the SqueezeTrigger Price before a short squeeze starts in any stock, go to http://www.buyins.net .
